{"id":"W3000295995","doi":"10.1093/ecco-jcc/jjz203.548","title":"P419 Clinical effectiveness and safety of first-line biologic vedolizumab as a monotherapy or combination therapy in ulcerative colitis and Crohn’s disease patients: results from the EVOLVE study","year":2020,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Takeda (Canada); St. Paul's Hospital","funders":"","keywords":"Vedolizumab; Medicine; Ulcerative colitis; Internal medicine; Adverse effect; Clinical trial; Crohn's disease; Combination therapy; Concomitant; Incidence (geometry); Retrospective cohort study; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002922852,0.0001719579,0.0007716924,0.0004180707,0.0001875873,0.0008747352,0.0002850357,0.000364551,0.00101601],"category_scores_gemma":[0.004514038,0.000103759,0.001181936,0.0008023428,0.0002656889,0.0005834391,0.0003927242,0.0004778983,0.0001610595],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006097343,"about_ca_system_score_gemma":0.0006142907,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001289449,"about_ca_topic_score_gemma":0.00253773,"domain_scores_codex":[0.9979368,0.000907155,0.0002410852,0.0002319246,0.000575793,0.0001071223],"domain_scores_gemma":[0.9952677,0.001659121,0.00198247,0.0001974217,0.0005632157,0.0003301346],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.06383426,0.001738628,0.8559959,0.0008890482,0.003871819,0.0001892492,0.0002091863,0.000624256,0.001481804,0.0001330067,0.00115609,0.06987683],"study_design_scores_gemma":[0.00675123,0.01786305,0.9668069,0.0001480669,0.002415313,0.0006235944,0.0002795649,0.001207295,0.001154563,0.00008770547,0.002628029,0.00003459698],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9948192,0.002783029,0.00009823948,0.00006733927,0.00001114742,0.00007971306,0.00105332,0.000004857703,0.001083164],"genre_scores_gemma":[0.9972379,0.0007294221,0.0002109894,0.00007404088,0.00003426632,0.00005193701,0.001425409,0.000002260497,0.0002337617],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002922852,"threshold_uncertainty_score":0.01545769,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01965262718479055,"score_gpt":0.2967467225061559,"score_spread":0.2770940953213654,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}